| Date | Title | | | 05/10/12 | Marina Biotech Receives Three Notices of Allowances From the USPTO
and an Intent to Grant Notice From the European Patent Office| Expands Patent Protection for SMARTICLES(R) and DiLA2(TM) Delivery Platforms
BOTHELL, WA, May 10, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based
drug discovery and development company, today announced that the U.S.
Patent and Trademark Office (USPTO) has issued a Notice of Allowance
for patent applications U.S. 12/004,154 ('154), U.S. 10/594,553
('553), and U.S. 10/505,107 ('107). Further, the European Patent
Office provided a notice of a... |
|  | | 05/08/12 | Marina Biotech Announces Worldwide Exclusive Licensing Agreement With
Monsanto| BOTHELL, WA, May 08, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA) announced today that it has
entered into an exclusive licensing agreement with Monsanto Company
for Marina Biotech's delivery and chemistry technologies. Terms of
the agreement were not disclosed.
"We are pleased to enter into this agreement with Monsanto, a global
leader in agriculture and crop sciences," stated J. Michael French,
President and Chief Executive Officer of Marina Biotech. "Over the
las... |
| | | 04/19/12 | Marina Biotech Regains Intellectual Property Rights to Its tkRNAi(TM)
Technology for Agriculture and Veterinary Uses| Cambridge Biolabs Will Still Maintain a License for Certain Veterinary Applications
BOTHELL, WA, Apr 19, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based
drug discovery and development company, today announced that it has
regained intellectual property rights to its transkingdom RNAi
(tkRNAi) drug discovery platform for both agriculture and veterinary
uses. The Company is currently developing a human therapeutic based
on the tkRNAi technolo... |
| | | 04/03/12 | Marina Biotech Completes Dosing of Second Cohort in the Phase 1b
START-FAP Clinical Trial of CEQ508| BOTHELL, WA, Apr 03, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based
drug discovery and development company, today announced the
completion of dosing for Cohort 2 in the Dose Escalation Phase of its
START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial
Adenomatous Polyposis) clinical trial with CEQ508. The three patients
of Cohort 2 received a dose of 1x10(9) colony forming units (cfu)/day
for up to 28 days of continuous oral ... |
| | | 03/19/12 | Marina Biotech, Inc. to Raise $1.2 Million in Registered Direct Offering| BOTHELL, WA, Mar 19, 2012 (MARKETWIRE via COMTEX) -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, announced that it has entered into definitive agreements with certain institutional investors for a registered direct placement of approximately $1.2 million of common stock at a price of $0.75 per share.
In addition, the Company will issue to the investors warrants to purchase up to 800,000 shares of common stock. The warrants have an ex... |
| | | 03/14/12 | Marina Biotech and ProNAi Therapeutics Announce License Agreement for
the Development of DNAi-Based Therapeutics| ProNAi Therapeutics Will Develop Oncology-Focused Compounds Utilizing Its Proprietary DNAi Technology Combined With Marina Biotech's Novel SMARTICLES(R) Liposomal Delivery Technology
BOTHELL, WA and ANN ARBOR, MI, Mar 14, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based
drug discovery and development company, and ProNAi Therapeutics, Inc.
(ProNAi), a privately-held biotechnology company pioneering DNA
interference (DNAi) therapies for cancer,... |
| | | 02/29/12 | Marina Biotech Presents Advances in Oral Delivery of Nucleic Acids at
AsiaTIDES Conference in Tokyo| Company Also Presents Data on Liposomal Facilitation of Cell-to-Cell Transfer of Nucleic Acids
BOTHELL, WA, Feb 29, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based
drug discovery and development company, today reported data
demonstrating the continued advancement of the Company's clinical
program for CEQ508, the only orally administered RNAi therapeutic in
clinical development. Data were also presented on early research in
the oral adminis... |
| | | 02/22/12 | Marina Biotech Receives Notice of Allowance for U.S. Patent Related
to Its Lipid Based Nucleic Acid Drug Delivery Platform| Expands Patent Protection for SMARTICLES(R) Delivery Technology
BOTHELL, WA, Feb 22, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based
drug discovery and development company, today announced that the U.S.
Patent and Trademark Office (USPTO) has issued a Notice of Allowance
for patent application U.S. 10/505,107 with claims that broadly cover
a library of nucleic acid delivery lipids related to its
SMARTICLES(R) delivery technology. The SMART... |
| | | 02/14/12 | Marina Biotech Announces Closure of Cambridge Site and Consolidation
of R&D Operations in Bothell, WA| Company Initiates Dosing in the First Patient in Cohort 2 of the START-FAP Clinical Trial
BOTHELL, WA, Feb 14, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based
drug discovery and development company, today announced the closure
of its Cambridge site and the consolidation of all research and
development efforts at its headquarters in Bothell, WA. In addition,
the Company announced dosing of the first patient in Cohort 2 in the
Dose Escalatio... |
| | | 02/10/12 | Marina Biotech Announces Closing of $1.5 MM Bridge Loan| BOTHELL, WA, Feb 10, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based
drug discovery and development company, today announced the closing
of a bridge loan pursuant to a Note and Warrant Purchase Agreement.
Under the terms of the loan, the Company sold promissory notes in the
aggregate principal amount of $1.5 million and issued warrants to
purchase an aggregate of approximately 3.7 million shares of the
Company's common stock at $0.508 per sha... |
| | | 02/01/12 | Marina Biotech Begins Trading on the OTCQX Tier of OTC Market| BOTHELL, WA, Feb 01, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based
drug discovery and development company, today announced that the
Company's common stock will begin trading on the OTCQX tier of the
OTC Markets commencing on Thursday, February 2, 2012. The Company has
been advised that its shares will trade under its current symbol,
"MRNA". Investors will be able to view real-time stock quotes for
"MRNA" at http://www.otcmarkets.com/stock/M... |
| | | 01/25/12 | Marina Biotech Starts Cohort 2 of Its Phase 1b START-FAP Clinical
Trial of CEQ508| Data Review Committee Determines CEQ508 Well Tolerated in Cohort 1 Patients
BOTHELL, WA, Jan 25, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (NASDAQ: MRNA), a leading nucleic acid-based
drug discovery and development company, today announced that Cohort 2
in the Dose Escalation Phase of the START-FAP (Safety and
Tolerability of An RNAi Therapeutic in Familial Adenomatous
Polyposis) clinical trial with CEQ508 will begin enrolling patients
in the next several weeks at Massachusett... |
| | | 01/23/12 | Marina Biotech Receives Notice of Acceptance for Patent Broadly
Covering Its Unlocked Nucleobase Analog (UNA) Technology| Patent Protects Use of UNAs in Multiple Nucleic Acid Constructs Including siRNAs, microRNA Mimics, Antagomirs and Single-Stranded Constructs
BOTHELL, WA, Jan 23, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (NASDAQ: MRNAD), a leading
oligonucleotide-based drug discovery and development company today
announced that the Intellectual Property Office of New Zealand
(IPONZ) has issued a Notice of Acceptance for patent application
580712. The claims broadly cover multiple sequence indep... |
| | | 01/10/12 | Marina Biotech, Inc. Provides Update on Its Broad Nucleic Acid-Based
Drug Discovery Platform and 2012 Goals| Through Partnership and Licensing Agreements, Marina Biotech's Drug Discovery Platform Brought in Over $1.5 MM in Non-Dilutive Capital in the Fourth Quarter of 2011
BOTHELL, WA, Jan 10, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (NASDAQ: MRNAD), a leading
oligonucleotide-based drug discovery and development company, will
provide an update on its nucleic acid-based drug discovery platform
and 2012 goals at Biotech Showcase 2012 on Tuesday, January 10, 2012,
at 5:30 p.m. Eastern T... |
| | | 01/06/12 | Marina Biotech, Inc. Closes Previously Announced $5 Million Financing| Financing Provides Flexibility to Execute on Pre-Clinical, Clinical and Partnering Objectives
BOTHELL, WA, Jan 06, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (NASDAQ: MRNAD), a leading
oligonucleotide-based drug discovery and development company,
announced today that it has completed the closing of the previously
announced equity investment of up to $5 million with Socius CG II,
Ltd. ("Socius"), a Bermuda-based subsidiary of Socius Capital Group,
LLC, and will be filing a regis... |
| | | 01/03/12 | Marina Biotech, Inc. to Present at Biotech Showcase 2012| BOTHELL, WA--(Marketwire -01/03/12)- Marina Biotech, Inc. (NASDAQ: MRNAD - News), a leading oligonucleotide-based drug discovery and development company, announced today that it will present at Biotech Showcase 2012 on Tuesday, January 10, 2012, at 5:30 p.m. Eastern Time (2:30 p.m. Pacific Time) at the Parc 55 Wyndham San Francisco in San Francisco. J. Michael French, Marina Biotech President and Chief Executive Officer, will present a corporate overview, the recent Mirna Therapeutics licensing ... |
| |
|
